Recent Updates
Recently added Catalysts

Forte Biosciences, Inc.

FBRX
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$76.99
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full FBRX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $10.1152W HIGH $77.20
Volume
1.40 M
Value Traded
58.78 M
Short % Float
9.85%
+0.05%Week
+0.51%1 Month
+300.16%3 Month
+151.19%6 Month
-97.64%5 Year
-99.44%All Time

Cash Data

Unlock FBRX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.58 B
EPS (TTM)
-4.14
P/E Ratio
-
Ent. Value
1.38 B
Total Shares
20.48 M
Float Shares
16.57 M
Insiders
18.48%
Institutions
74.56%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1b data readout
FB102
Alopecia areata
Phase 1bBiologicsDermatologic System
Unlock every FBRX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

FBRX Catalyst Timeline

Dated clinical, regulatory and corporate events for Forte Biosciences, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Forte Biosciences, Inc.

185Total events
1Upcoming
45Tier-1 (high impact)
2017 to 2026Coverage

Upcoming catalysts 1

T1Topline Readout
Subscribe to view catalyst details
FB102

Event history 50

▲AcquiredCorporate
argenx completes acquisition of Forte Biosciences
source ↗
◆AcquisitionCorporate
argenx commences tender offer to acquire Forte Biosciences
source ↗
◆AcquisitionCorporate
argenx to acquire Forte Biosciences for $77 per share
source ↗
●Quarterly UpdateCorporate
argenx investor conference call to discuss transaction
source ↗
▲Topline ReadoutFB102Clinical Data
Positive Phase 1b data in vitiligo reported
vitiligosource ↗
◆AcquisitionCorporate
Acquisition expected to close in Q3 2026
source ↗
▲Topline ReadoutFB102Clinical Data
Vitiligo trial data reported
vitiligosource ↗
●Quarterly UpdateCorporate
First quarter 2026 results
source ↗
▲Fast Track DesignationFB102Designation
FB102 received Fast Track Designation from FDA in celiac disease
celiac diseasesource ↗
◆Topline ReadoutFB102Clinical Data
Topline results from Phase 1b vitiligo study expected shortly
vitiligosource ↗
Unlock the full FBRX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How FBRX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30FB102 Phase 1b topline data readout Phase 1b
Unlock 1 more FBRX historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C44 / 100
Pipeline Score
$160M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Forte Biosciences, Inc. carries a moderate pipeline score (44/100), with $400M risk-adjusted pipeline value, led by FB-401 in Atopic Dermatitis (Phase 2).
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
FB-401 Monoclonal antibodyCompletedNCT04504279Atopic DermatitisPhase 2 COMPLETED 154Aug 19, 2021
Unlock the FBRX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every FBRX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
FB102
Fast Track
vitiligoPhase 1b2026-07-0929.6% mean improvement in the FVASI score at week 24 (p-value = 0.020)Read MoreFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodRead More
Scroll for more · summaries link to the source press release
Unlock every FBRX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock FBRX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Wagner Paul A.Director, Officer (SEE REMARKS)Option 1,250 85,580 held$0.00 07/01/2026
Unlock the full FBRX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in FBRX

Fund % of Portfolio Current MV Shares Owned Activity
ORBIMED ADVISORS LLC 0.6 % 33.53 M 1.58 M 31.81% ( 380.75 K)
Unlock every fund holding FBRX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in FBRX
Shares held by hedge funds each quarter, and who bought or sold.

FBRX Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock FBRX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live FBRX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock FBRX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How FBRX ranks across every disease it competes in

Competitive Position is a premium feature
See how FBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

FBRX News

About Forte Biosciences, Inc.

Dallas, TX 23 employees fortebiorx.com
Headquarters3060 PEGASUS PARK DRIVE, DALLAS, TX, 75247
BIOPHARMAWATCH ELITE PLUS
Trade the next FBRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime